Alejandro Rojas‐Fernández

This paper describes the engineering of a PROTAC that uses p97-directed proteolysis to achieve specific substrate degradation without relying on E3 ubiquitin ligases.

This paper develops a bispecific antibody that targets both Nipah virus surface glycoproteins, reducing viral escape and enhancing protection against NiV disease.

This paper develops a novel nanobody library assembly technique for targeting IPNv VP2 protein, identifying specific nanobodies with diagnostic potential.

This study shows senolytic drugs reduce brain aging and COVID-19-related neuropathology by targeting senescent cells in human brain organoids and mice.

This study shows SARS-CoV-2 activates microglial NLRP3 inflammasome via spike-ACE2 interaction, potentially linking viral infection to neurological symptoms like Parkinson's.

The paper describes the development of a high-affinity Nanobody against SARS-CoV-2 RBD that neutralizes wild-type and D614G variants with nanomolar potency.